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A20, also known as TNF-alpha-induced protein3
(TNFAIP3), is a well-known negative regulator of the NF-
kB activation pathway (Coornaert et al. 2009; Stilo et al.
2008) and functions as a tumor suppressor gene in
lymphomas (Honma et al. 2009; Kato et al. 2009). Aberrant
NF-kB regulation in colorectal carcinoma (CRC) is associ-
ated with poor prognosis and resistance to therapy (Horst et
al. 2009; Kojima et al. 2004; Rakitina et al. 2003; Scartozzi
et al. 2007). The current study deals with an interesting and
novel topic about oncogenic role of inactivation of tumor
suppressor gene A20 in colorectal cancer, the mechanism of
A20 dysfunction, and its potential as a novel prognostic
marker and therapeutic target. This is the first report of A20
alterations in colon cancer where we comprehensively
investigated the genomic profile and epigenetic changes in
A20 gene.
A better understanding of NF-kB modulators could lead to
development of effective therapeutic strategies to target
activated NF-kB (Rakitina et al. 2003). Mechanistically,
A20 exerts its NF-kB inhibitory role in TNF signaling by
the cooperative and dual-functioning actions of the deubiqui-
tinating and ubiquitinating enzyme activities located at the N
and C terminus, respectively, of the A20 protein (Coornaert et
al. 2009). The amino terminal of A20 protein containing the
deubiquitinating enzyme targets removal of ubiquitin moieties
from receptor-interacting protein (RIP1), an essential media-
tor of the proximal tumor necrosis factor receptor signaling
complex in NF-kB activation (Wertz et al. 2004). This is
followed by polyubiquitination of RIP by the ubiquitin ligase
located at the carboxy terminal of A20 protein, thereby
targeting RIP for proteosomal degradation. Recent studies
have shown that A20 functions as a tumor suppressor gene in
several types of lymphoma wherein not only is A20
inactivated by promoter methylation (Chanudet et al. 2009),
but it is also subject to gene deletion and mutation. Although
A20 has been reported as a novel tumor suppressor gene in
NHLs, the role of A20 in colorectal carcinoma is not yet
known. In this study, we screened for A20 gene copy number
changes and A20 expression in a large tissue microarray
cohort of 434 colorectal carcinomas and adenoma samples.
We further investigated the incidence of A20 mutations and
A20 promoter methylation and the relationship of A20
alterations with CRC progression and phenotype.
The incidence of A20 mutations, A20 deletions, A20
promoter hyper-methylation was 2.5%, 15.3%, and 50.8%,
respectively. We analyzed the entire coding region of A20
gene in 116 CRC samples and 14 CRC cell lines and found
that only three CRC samples and two CRC cell lines
(LOVO and HCT-15) were mutated. Most of the A20
mutations found in Hodgkin's and mediastinal lymphomas
were nonsense or frameshift mutations that prevented
production of full-length A20 protein (Chanudet et al.
2009; Honma et al. 2009; Schmitz et al. 2009). The three
A20 mutations found in our study were replacement
mutations. Two of these three mutations in our study were
localized in the zinc finger (ZF) domains at the C terminus
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of the protein. The A20 ZF domain functions as an E3
ubiquitin ligase, adding K48-linked polyubiquitin chains to
RIP1 and targeting the protein for proteasomal degradation.
Most of the mutations seen in the three CRC samples as
well as the two cell lines were missense mutations (four out
of five). A20 deletions were seen in 15.3% (65/424) of the
CRC samples analyzed by FISH. Homozygous deletions, i.
e., presence of two centromeric signals but no A20 signals,
were seen in four of the 65 (3.1%) deleted cases. Although
A20 mutations were not observed in the CRC with A20
deletions, six cases showed co-existence of A20 methylation
and A20 deletions. Thus, A20 alterations are widely prevalent
in colorectal carcinoma, and A20 promoter methylation leads
to reduced expression of A20 protein.
A20 promoter hyper-methylation was correlated with
loss of protein expression and associated with histology
subtype of adenocarcinomas differentiated tumors and CRC
located on the left side. A20 protein expression was
significantly higher in colorectal adenomas as compared
to colorectal carcinomas. A20 expression identifies a
subgroup of colorectal cancers which show a poor outcome
across all subgroups, in stage III alone, stage II and III
subgroup, and also stage III and IV subgroup. Reduced
A20 expression was an independent prognostic marker in
colorectal carcinoma. Together, our results establish A20 as
a key tumor suppressor molecule in colorectal carcinogen-
esis and identify a subgroup of CRC patients with reduced
A20 expression showing a poor overall survival. A20
promoter methylation is the key epigenetic mechanism
leading to suppression of A20 expression. Interestingly,
complete loss of A20 expression results from multiple hits
like A20 deletion and or mutation with methylation in
accordance with Knudson's two-hit hypothesis. Our find-
ings indicate that A20 is a tumor suppressor in CRC that
can be used as a potential prognostic biomarker.
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